October 2022
We are happy to announce that we raised over $37,000 at our 35th Anniversary Commemoration Brunch at the Belvedere on September 18, 2022! The generous donations of our event sponsors and our loyal supporters listed below will allow us to continue our important HIV prevention programs, drug research and treatment access advocacy, and to provide valuable financial, educational and emotional support to people with HIV infection.
The generous financial donations of our sponsors and supporters as well as the time and effort of our loyal volunteers has made a real difference for us again this year. It means so much to us to receive your continued help and support. We work so hard. It means the world to us to know that people know that we are in the trenches and doing our best to continue the fight against AIDS.
On behalf of the AAB Board and volunteers, thank you all of you who attended our event as well as those of you who helped to make it a success. We hope you all had a wonderful time. Please know that your assistance makes a real difference in the fight against AIDS and the ability to keep our doors open. Without people like you, there would be no AIDS Action Baltimore.
Sponsors
Maryland Department of Health
Simply Beautiful Flowers
Auction Donors
Maryland Live Casino
Radcliffe Jewelers
Donors
Anonymous
Chuck Bowers
David Fogle & John Miller
John LeBedda, II
Paul Matassa & Rennie Hiltz
Tark’s Grill & Bar
Lorie Yagjian
In Memoriam: John G. Bartlett, MD
By Richard E. Chaisson, MD
Dr. John Bartlett, an iconic and visionary leader in infectious diseases and HIV/AIDS died on January 19, 2021, at the age of 83. Dr. Bartlett was an original principal investigator in what became the AIDS Clinical Trials Group and a legendary scientist, clinician, teacher, and writer who made major contributions to an astonishingly wide range of infectious disease threats. In addition to his leadership within the ACTG, Dr. Bartlett played a pivotal role in leading numerous other professional and public health entities, including co-chairing the Department of Health and Human Services HIV Guidelines Panel, serving as president of the Infectious Diseases Society of America, and chairing the board of directors of Baltimore’s Health Education Resources Organization (HERO), one of the earliest AIDS advocacy groups in the country.
Born in upstate New York, John studied medicine at SUNY Syracuse, was an intern at the Peter Bent Brigham Hospital in Boston, and a resident at the University of Alabama, Birmingham, where he planned to become a cardiologist. He was drafted into the US Army in 1965 and sent to Vietnam where he helped run a hospital that cared for soldiers with a variety of infections. Returning to the US, he decided to study infectious diseases because “you can look in the microscope and see the enemy.” He began studying anaerobic infections and helped elucidate the causes of both pulmonary and abdominal infections caused by anaerobes, publishing a number of seminal papers on the subject. He then focused his attention on antibiotic-associated colitis, and discovered the toxin produced by Clostridium difficile (C. diff) that caused the disease. His landmark study of C. diff colitis, published in the New England Journal of Medicine, led to the development of diagnostic tests and treatments for this extremely common and debilitating disease.
John was recruited to Johns Hopkins School of Medicine in 1980 to lead the Infectious Disease division and over the next 26 years built it into a global leader across the entire spectrum of infectious diseases. In 1982, his interests shifted to the AIDS epidemic and he and his colleague Frank Polk mobilized resources within the institution to both care for patients and better understand the disease. He created the second dedicated inpatient AIDS ward in the world, after San Francisco General Hospital, and recruited a multidisciplinary team of clinicians to provide care and develop treatments.
Over the next 30+ years he became an internationally renowned expert in HIV therapeutics, always driven by his own direct involvement in caring for patients. John maintained a busy clinic caring for people with HIV and other infections, taught on the inpatient wards, and always attended on the AIDS Ward on Christmas, giving gifts to every patient while wearing a Santa hat. He befriended Garey Lambert, a prominent local AIDS activist who had written highly critical articles about the medical community’s response to the epidemic. John and Garey became close friends; Garey relied on John’s insights into HIV research, and John brought Garey to scientific meetings, including ACTG meetings, to both learn and provide community perspective to researchers and clinicians. Following Garey’s death, the Hopkins HIV Research Clinic was named in his honor, and a large portrait of Garey hung over John’s desk for the remainder of his career.
John was one of the most sought-after speakers on HIV and infectious diseases. He lectured around the world with an absolutely brilliant ability to synthesize data, explain it to scientists, clinicians, and laypeople, and look into the future to predict what would come next. John’s Top Ten lists of advances in HIV and Infectious Diseases were extremely popular talks at conferences and have been emulated by many. He was an early adopter of internet tools, establishing an HIV website, conducting online clinical conferences for clinicians in Ethiopia, Uganda, and India, and pioneering telemedicine for inmates in the Maryland state prison system. His teaching in the classroom and at the bedside was equally awe-inspiring, with his encyclopedic knowledge and insightful interpretation. He wrote prodigiously, producing dozens of books, including his Pocket Guide to HIV Infection and The Medical Management of HIV Infection, now in their 19th and 17th editions, respectively. In addition to HIV, he was a leader in areas as diverse as bioterrorism, emerging infections, community-acquired pneumonia, and antimicrobial resistance.
John was famed for his extraordinary work ethic, maintaining a schedule that made most people weary just to think about. He arrived at his office in the wee hours of the morning and worked for 15 hours, but still managed to be home for dinner and spend the evening with his wife Jean and their three children, Valerie, Josh, and Scott. He explained his secret to me once when he returned from a two-week vacation with Jean in Australia and showed me the hand-written manuscript he had produced while they were there, the first edition of his Pocket Guide to HIV/AIDS. I scolded him and told him he was supposed to have been on vacation, and he responded, “Yes, but you have to understand that Jean sleeps at night.” In addition to time spent with his family, John was a talented artist, and he once took a sabbatical to Paris to paint.
Following his retirement in 2014, John and Jean moved to Tupelo, Mississippi, where he continued to write, read, lecture, and serve on committees, but he was able to spend even more time with friends and family. John’s beloved wife Jean Bartlett died in October, 2020.
In 2016 the Johns Hopkins HIV and viral hepatitis clinics were merged in a magnificent new facility named The John G. Bartlett Specialty Practice. The clinic continues the work that John began 36 years ago, caring for people from all walks of life with HIV infection.
John’s death is a huge loss to the HIV and medical communities. He commented at his retirement, “It would be difficult to find another discipline in medicine that has such extraordinary diversity, surprises, value in patient care, and clinical relevance for both domestic and international applications.”1 It would be difficult to name another individual who contributed more to our understanding of, provided better care for, or helped educate more practitioners to combat the diverse spectrum of microbes that threaten human health and happiness than John Bartlett.
_____________________________________
1 Bartlett JG. Why infectious diseases. Clin Infect Dis. 2014, 59(suppl 2):S85–S92,
AIDS Action Baltimore forces Moderna and Pfizer to include people in their COVID-19 Vaccine Trials
COVID-19 Vaccine Trial Advocacy Letter to Moderna
https://www.aidsactionbaltimore.org/wordpress/wp-content/uploads/2020/07/COVID-19-Vaccine-Trial-Advocacy-Letter.pdf
COVID-19 Vaccine Trial Advocacy Letter to Pfizer
https://www.aidsactionbaltimore.org/wordpress/wp-content/uploads/2020/08/Pfizer-Vaccine-Trial-HIV-HBV-HCV-Exclusion-Letter.pdf
amFAR Article
https://www.amfar.org/Vaccine-Trial-Victory/
Bloomberg Article
https://www.bloomberg.com/news/articles/2020-08-06/moderna-backtracks-to-open-covid-vaccine-trial-to-those-with-hiv?sref=9f0rXTjL
POZ Article
https://www.poz.com/article/will-people-hiv-excluded-covid19-vaccine-trials
Science Magazine Article
https://www.sciencemag.org/news/2020/08/groups-protest-exclusion-hiv-infected-people-coronavirus-vaccine-trials
AIDS ACTION BALTIMORE, INC.
14 EAST EAGER STREET, BALTIMORE, MARYLAND 21202
(410) 837-2437, FAX (410) 837-2438
BaltoAIDS@aol.com http://aidsactionbaltimore.org
Dear Friends:
AIDS Action Baltimore (AAB) has been providing essential services to people with HIV/AIDS since 1987. Thanks to your generosity, we’re still standing. We all know only too well that times are still tough, but as we commemorate our 35th year of service, we hope we can count on your continued support which will help us maintain our many HIV/AIDS programs. We still desperately need your help to keep our doors open and continue to provide our many essential services to the Baltimore HIV/AIDS community. We hope you will remember us and continue your loyal support. Please help us in any way you can. Your donations will enable us to continue our marvelous record of benevolence and compassion with only a rate of 4.3% overhead in 2021. The amount of work we accomplish and the effect we have had on the war against HIV with only four employees is truly amazing!
Although HIV disease is becoming a chronic manageable disease, here is why we still need your help now more than ever:
AAB still provides financial assistance to many needy people with HIV/AIDS. AAB has provided this support to over 8,800 people since 1987 and $3,186,000 in assistance for items such as rent and utilities, and direct programs in our community to people with HIV/AIDS and their families. We firmly believe we must continue our invaluable financial assistance program which provides a safety net to people with HIV/AIDS experiencing an emergency financial crisis.
In the latest Centers for Disease Control (CDC) data reported in 2021, Maryland was ranked 12th among U.S. states and territories in adult/adolescent HIV diagnosis rates (per 100,000) in 2020. At the end of 2021, there were 32,149 people aged 13 and older living with diagnosed HIV in Maryland. An estimated 3,400 people with HIV (PWHIV) in Maryland in 2020 remain undiagnosed.
AAB has been instrumental again this year in reducing HIV transmission in Baltimore. According to the CDC, the lifetime risk of HIV is one in 22 for Black males, one in 51 for Latinx males, and one in 140 for White males. We are currently administering an HIV PrEP prevention program, known as New Horizons. PrEP is a one pill, once a day pill that has proven to be 99% effective in reducing HIV transmission risk. Our HIV prevention program provides outreach, education, testing assistance, healthcare linkages, navigation support and support groups that promote medication adherence for African-American Transgender (Trans) people and Gay men at risk of HIV, and also for people who are HIV positive. We also provide our clients with the latest in HIV prevention and treatment research information.
New Horizons promotes a continuum of care HIV prevention and/or HIV treatment including retention in care and adherence to life-saving medications in Gay men and Trans people as well. Our prevention and treatment efforts have been extremely successful. We seek to educate Black Gay men and Trans people about their exorbitant risk of HIV transmission, and help them build networks of support to combat the many social obstacles they encounter daily which contribute to their risk of HIV, causing them to fall in and out of care and treatment. We have also been educating people about Treatment as Prevention (TASP), also known as U=U (Undetectable HIV = Untransmittable HIV). If a person’s HIV viral load is undetectable, they cannot transmit HIV to another person! We are very proud of our very successful support and education programs which have helped to decrease HIV as well as the number of PWHIV we have helped to access and remain on life-saving HIV medications. AAB can continue to provide these life-saving programs with your help.
Our national work affects all who are touched by HIV/AIDS. We are working with industry to continually change the standard of care by ensuring that their new drug pipelines remain robust, and by replacing older more toxic drugs with more effective, better tolerated drugs, as well as exciting new long-acting drugs for HIV prevention and treatment that may require only daily, weekly or monthly dosing. This is the wave of the future.
AAB has been instrumental in the formation of the Drug Development Committee of the AIDS Treatment Activists Coalition, a national organization that interacts with the pharmaceutical industry, pressuring companies to study drugs expeditiously and ethically and to include the HIV affected community in all aspects of research and development. AAB has also been a leading member of the national Fair Pricing Coalition (FPC), pressuring “big pharma” to price HIV drugs reasonably, limit price increases, cap ongoing drug prices for government programs like AIDS Drug Assistance Programs, and to initiate co-pay programs for patients with private insurance. We convinced every HIV and Hepatitis C drug company to create programs that will cover outrageously expensive co-pays and other out of pocket (OOP) costs for people with private insurance. Our work directly affects Marylanders with ever increasing OOP prescription costs. We are also working very hard to ensure that people in Maryland and across the country who cannot afford their medications get their drugs for free from “big pharma” through Patient Assistance Programs (PAPs). These OOP co-pay programs are being discontinued by insurance providers. AAB has been trying to work in collaboration with numerous national organizations to preserve co-pay programs which have recently come under attack by healthcare insurance companies. We are also currently leading a coalition of local service providers to make sure the Maryland AIDS Drug Assistance Program begins to function properly after the hack of Maryland Department of Health’s computers. With the help of this coalition and your continued support, we will be able to ensure that PWHIV receive their HIV medications without further interruptions.
We are very excited that scientists have begun to work on HIV “cure- related” research. AAB is working with government, industry and the national HIV community nationally to make a “cure” for HIV or what we are now calling “durable HIV suppression” a reality. Even though this will take years to come to fruition, we have to start somewhere. AAB is a member of the DARE Martin Delaney Cure Research Collaboratories. AAB is also working with DARE researchers to bring additional resources to Baltimore for local cure research projects. We conducted four HIV Cure Forums in 2019 to 2022.
HIV policy gets more complicated every year. COVID-19 is still eating a large percentage of US Health and Human Services (HHS) funding. We are in danger of losing all our hard-won treatment and prevention gains. Because of COVID-19, it is much harder to obtain the money we need to fight HIV. We are working very closely with the Baltimore City Health Department (BCHD) in their End the HIV Epidemic Initiative. The BCHD has also provided funding for our prevention and treatment programs. We had nine Town Halls in conjunction with the BCHD from 2020 to 2022, discussing new HIV and COVID-19 news. Innovative events like this would not happen without AIDS Action Baltimore.
AAB successfully advocated for increased NIH HIV research funding, and will continue to advocate for other HHS budget increases, like continued funding for the Ryan White Care Act for the support of people with HIV. We continue to advocate for COVID-19 support for people with HIV. We are using our many years of government research and policy expertise and connections in the fight against COVID-19. AAB was instrumental in ensuring that PWHIV were not excluded from COVID-19 vaccine protocols, and worked tirelessly to ensure that PWHIV were finally prioritized for COVID-19 vaccinations both nationally and in Maryland. We spearheaded many months of high-level advocacy, collaborating with national activists to ensure that PWHIV were included in COVID-19 vaccine trials and prioritized for vaccines.
We know that many of you have suffered too during the COVID-19 crisis. AAB helped to fund local COVID-19 food insecurity efforts for people with HIV, and expanded our financial assistance programs for PWHIV who have COVID-19 emergencies. During the initial shut-down, we sent needy clients COVID-19 care packages that included masks, hand sanitizer and important COVID-19 information. Please be sure to contact us if you think any of our many programs might be of assistance to you or your friends and family.
We have been fierce advocates of expanded vaccines and treatment for monkeypox for our community at both the federal and state levels. AAB has also conducted a Town Hall in collaboration with the Maryland Department of Health, Johns Hopkins and the Pride Center of Maryland in an effort to inform people of the risk of monkeypox as well as how and where to access vaccines and treatment. Advocating for life-saving vaccines and treatments has been our life’s work. Our expertise and long-standing contacts in these arenas are invaluable. Our work is way ahead of the curve. The type of advocacy done by AAB does not happen in any other disease community.
Our city and country need the expertise of AIDS activists now more than ever. As always, we will continue to work locally and nationally for PWHIV as well as COVID-19 and monkeypox issues. With your help, we can continue to keep our doors open to face these other infectious diseases that affect our community. But we cannot do it without your help. Please contribute as much as you can to help us keep our doors open at this critical time in our history.
We are still doing our best to help ourselves. AAB raised $40,000 at our lovely 35th Anniversary Commemoration event at the Belvedere on September 18, 2022. AAB honored John Waters and Pat Moran, Carla Alexander, MD and Richard Chaisson, MD and Debbie Rock and Carlton Smith at our 35th Anniversary event.
Please help us to continue our life-saving programs and our vital local and national research and treatment advocacy. We greatly appreciate your continued support in these tough economic times. Thank you in advance for your contribution and for your past generosity. We know you are called on to make many contributions. We very much appreciate your continued confidence in our work. Your donation will help us to save lives. We are forever grateful for your trust and loyal support. Remember, now more than ever, without people like you, there would be no AIDS Action Baltimore! We hope you and yours remain safe and well.
Sincerely, Lynda Dee & the AAB Board
Merle McCann, M.D., Chair
Michael Aquino
Kenny Eggerl
Thomas Holden
Mark McMullen
Jake Boone, III
Cameron Wolf, Ph.D., M.P.H.
Our current financial statement is available upon request by contacting AIDS Action Baltimore at 14 East Eager Street, Baltimore, MD 21202 or (410) 837-2437. Documents and information submitted to the State of Maryland under the Maryland Charitable Solicitations Act are available from the Office of the Secretary of State, State House, Annapolis, MD 21401 for the cost of copying and postage.
COVID-19 and People Living with HIV
Frequently Asked Questions
Link to English FAQ: http://www.HIV-covid.org/
Link to Spanish FAQ: http://www.VIH-covid.org/